melanocortin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Chronic constipation is especially common, and is thought to be aggravated by an asymmetric pelvis (acetabular protrusion). Especially in childhood, OI-associated constipation may cause a feeling of fullness and associated food refusal, leading to malnutrition.
Indium is produced exclusively as a by-product during the processing of the ores of other metals. Its main source materials are sulfidic zinc ores, where it is mostly hosted by sphalerite. Minor amounts are also extracted from sulfidic copper ores. During the roast-leach-electrowinning process of zinc smelting, indium accumulates in the iron-rich residues. From these, it can be extracted in different ways. It may also be recovered directly from the process solutions. Further purification is done by electrolysis. The exact process varies with the mode of operation of the smelter. Its by-product status means that indium production is constrained by the amount of sulfidic zinc (and copper) ores extracted each year. Therefore, its availability needs to be discussed in terms of supply potential. The supply potential of a by-product is defined as that amount which is economically extractable from its host materials per year under current market conditions (i.e. technology and price). Reserves and resources are not relevant for by-products, since they cannot be extracted independently from the main-products. Recent estimates put the supply potential of indium at a minimum of 1,300 t/yr from sulfidic zinc ores and 20 t/yr from sulfidic copper ores. These figures are significantly greater than current production (655 t in 2016). Thus, major future increases in the by-product production of indium will be possible without significant increases in production costs or price. The average indium price in 2016 was US$240/kg, down from US$705/kg in 2014.
Deka Bike Robo (デカバイクロボ, Deka Baiku Robo): The Deka Bike's Tokusou Transformation and Deka Break's personal giant robot that is equipped with the twin wrist-mounted Sleeve Swords (スリーブソード, Surību Sōdo), which allow it to perform the Sword Tornado (ソードトルネード, Sōdo Torunēdo) finisher. Deka Wing Robo (デカウィングロボ, Deka Wingu Robo): The Dekarangers' second giant robot composed of the Pat Wings that dual wields the twin Pat Magnum (パトマグナム, Pato Magunamu) handguns, specializes in aerial and zero-g combat, and can perform the Double Heel Smash (ダブルヒールスマッシュ, Daburu Hīru Sumasshu) attack. It can also transform further into the Deka Wing Cannon (デカウィングキャノン, Deka Wingu Kyanon) to perform the Final Buster (ファイナルバスター, Fainaru Basutā) finisher on its own; the All Star Ultimate Buster (オールスター・アルティメットバスター, Ōru Sutā Arutimetto Basutā) finisher with Dekaranger Robo, Deka Bike Robo, and Deka Base Robo; and the Twin Robo Ultimate Buster (ツインロボ・アルティメットバスター, Tsuin Robo Arutimetto Basutā) with Deka Bike Robo. In the crossover film Mahō Sentai Magiranger vs. Dekaranger, the Deka Wing Cannon performs the Magi Final Buster (マジファイナルバスター, Maji Fainaru Basutā) finisher alongside the Magirangers' giant robot Magi Legend.
Sources: en.wikipedia.org
Homocysteine (symbol Hcy) is a non-proteinogenic α-amino acid. It is a homologue of the amino acid cysteine, differing by an additional methylene bridge (−CH2−). It is biosynthesized from methionine by the removal of its terminal Cε methyl group. Although the production of homocysteine is a normal part of the metabolism of methionine, an excess of homocysteine can be harmful. There are two primary ways for organisms such as humans to metabolize homocysteine: remethylation and transsulfuration. Remethylation adds a methyl group to the homocysteine molecule, converting homocysteine back into methionine. There are two known remethylation pathways. One pathway requires vitamin B9 (folate) and B12 (cobalamin), which drive the MTR (methionine synthase) and MTRR (methionine synthase reductase) enzymes. The other pathway uses TMG (trimethylglycine) to drive the BHMT (betaine-homocysteine methyltransferase) enzyme. Transsulfuration converts homocysteine to cystathionine. This pathway requires vitamin B6 to drive the CBS (cystathionine beta synthase) enzyme. Cystathionine is the immediate precursor of the amino acid cysteine, which (along with glutamate and glycine), is incorporated into the tripeptide glutathione, a major antioxidant in the human body. Homocysteine is therefore an important metabolic substrate. However, excessive levels of homocysteine can result in hyperhomocysteinemia, which is regarded as an indicator of cardiovascular disease risk. Homocysteine likely contributes to atherogenesis, which can result in ischemic injury.
=== Federal jurisdiction === The act provided for federal court jurisdiction to enforce collective bargaining agreements. Although Congress passed this section to empower federal courts to hold unions liable in damages for strikes violating a no-strike clause, this part of the act has instead served as the springboard for creation of a "federal common law" of collective bargaining agreements, which favored arbitration over litigation or strikes as the preferred means of resolving labor disputes.
Positive health of a person is defined as the ability to live long in good health without activity limitation. This implies the availability of mechanism in the body to thwart the ailments and to minimize their adverse effect if they strike. The concept has evolved over time and has seen significant changes.
Sources: en.wikipedia.org
In 2005, Sean Kinney came up with the idea of doing a benefit concert for the victims of the tsunami disaster that struck South Asia in 2004. Kinney made calls to his former bandmates, as well as friends in the music community, such as former Alice in Chains manager Susan Silver. Kinney was surprised by the enthusiastic response to his idea. On February 18, 2005, Jerry Cantrell, Mike Inez, and Sean Kinney reunited to perform for the first time in nine years at K-Rock Tsunami Continued Care Relief Concert in Seattle. The band featured Damageplan vocalist Pat Lachman, as well as other special guests including Maynard James Keenan of Tool, Wes Scantlin of Puddle of Mudd and Ann Wilson of Heart. A few months after that experience, the band called Susan Silver and Cantrell's manager Bill Siddons and said they wanted to tour as Alice in Chains again. Alice in Chains was approached by the producers of the CBS reality show Rock Star about being featured on its second season, but the band turned the offer down. In the show, aspiring singers competed to become the lead vocalist of a featured group. On March 10, 2006, the surviving members performed at VH1's Decades Rock Live! concert, honoring fellow Seattle musicians Ann and Nancy Wilson of Heart. They played "Would?" with vocalist Phil Anselmo of Pantera and Down and bass player Duff McKagan of Guns N' Roses and Velvet Revolver, and at the end of the performance Cantrell dedicated the show to Layne Staley and the late Pantera and Damageplan guitarist Dimebag Darrell.
=== Cellulose nanofiber plate === A bottom up approach can be used to create a high-performance bulk material with low density, high strength and toughness, and great thermal dimensional stability: cellulose nanofiber plate (CNFP). Cellulose nanofiber hydrogel is created by biosynthesis. The hydrogels can then be treated with a polymer solution or by surface modification and then are hot-pressed at 80 °C. The result is bulk material with excellent machinability. "The ultrafine nanofiber network structure in CNFP results in more extensive hydrogen bonding, the high in-plane orientation, and "three way branching points" of the microfibril networks". This structure gives CNFP its high strength by distributing stress and adding barriers to crack formation and propagation. The weak link in this structure is bond between the pressed layers which can lead to delamination. To reduce delamination, the hydrogel can be treated with silicic acid, which creates strong covalent cross-links between layers during hot pressing.
== Background == Descriptions of rejuvenation and immortality remedies are often found in the writings of alchemists. But all those remedies did not allow even alchemists themselves to live longer than a hundred years. Though the average lifespan of people through the past millennia increased significantly, maximum lifespan almost did not change - even in ancient times there were fairly well and unbiasedly documented cases when some people lived for more than a hundred years (for example, Terentia who lived 103 or 104 years). While among the billions of people of the modern world, there is only one case of life over 120 years (Jeanne Calment, 122 years). The super-long lives of people that are mentioned in ancient books, apparently, are highly exaggerated, since archaeological data show that even the oldest of the ancient people lived no more than modern supercentenarians. In some cases the exaggeration, possibly, is not intentional but occurs due to errors in translation between languages and synchronization of chronological systems. The species limit of human life is estimated by scientists at 125–127 years, and even in the most ideal conditions a person will not live longer due to aging of the body. Some scientists believe that, even if medicine learns how to treat all major diseases, that will increase the average lifespan of people in developed countries by only about 10 years. For example, biogerontologist Leonard Hayflick stated that the natural average lifespan for humans is 92 years.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.